Cabozanix 20MG & 60MG (Cabozanitib)

Basic Product Information of Cabozanix 20MG & 60MG (Cabozantinib)

How Cabozanix 20MG & 60MG (Cabozantinib) Works Multi-Kinase Inhibition of VEGFR, MET, AXL, and RET

Cabozantinib, the active ingredient in Cabozanix 20MG & 60MG, is a potent small-molecule multi-kinase inhibitor that simultaneously blocks several receptor tyrosine kinases (RTKs) central to tumour biology: VEGFR-1, VEGFR-2, VEGFR-3 (anti-angiogenic axis), MET (hepatocyte growth factor receptor), AXL (TAM family kinase), RET (rearranged during transfection), KIT, and FLT3. This multi-target profile distinguishes Cabozanix from single-pathway VEGFR inhibitors such as sunitinib or axitinib, enabling it to simultaneously suppress tumour vascularisation and overcome the resistance mechanisms that commonly develop after first-line anti-angiogenic therapy.

The IC50 values of Cabozantinib reflect its exceptional potency: VEGFR-2 at 0.035 nmol/L, MET at 1.3 nmol/L, KIT at 4.6 nmol/L, RET at 5.2 nmol/L, AXL at 7 nmol/L, and FLT3 at 11.3 nmol/L. In Renal Cell Carcinoma, inactivation of the Von Hippel-Lindau (VHL) tumour suppressor gene leads to upregulation of VEGF, MET, and AXL all three of which are directly inhibited by Cabozanix. Critically, chronic use of earlier VEGFR inhibitors (sunitinib, sorafenib, axitinib) drives tumour escape via MET and AXL upregulation. By simultaneously blocking both pathways, Cabozanix rescues acquired VEGFR-TKI resistance that renders tumours insensitive to earlier-generation targeted agents. Preclinical studies confirmed that in sunitinib-resistant models, Cabozantinib suppressed both MET and AXL activation and restored tumour growth control.

Beyond its anti-angiogenic and anti-resistance activity, Cabozantinib exerts immunomodulatory effects within the tumour microenvironment (TME) by inhibiting TAM family kinases (TYRO3, MER, and AXL), which normally suppress anti-tumour immune responses. This immunological mechanism provides a strong biological rationale for the combination of Cabozanix with immune checkpoint inhibitors such as nivolumab, as validated in the CheckMate-9ER first-line RCC trial. Oncologists managing complex multi-line cancer treatments can review the complete oncology medicines portfolio at Mediaid Pharmacy for combination partners and other targeted cancer therapies.

Approved Indications for Cabozanix 20MG & 60MG (Cabozantinib)

Cabozanix (Cabozantinib) 20mg and 60mg is approved for the following oncological indications in adult patients:

Key Clinical Benefits of Cabozanix (Cabozantinib) 20mg and 60mg

How to Take Cabozanix 20MG & 60MG (Cabozantinib) Dosage and Administration Guidelines

Clinical Monitoring Requirements During Cabozanix (Cabozantinib) Treatment

Comprehensive clinical monitoring is mandatory throughout Cabozanix treatment. Blood pressure must be monitored and hypertension controlled before and throughout therapy; uncontrolled hypertension warrants dose interruption and antihypertensive management. Electrolytes particularly serum calcium, potassium, and phosphate require regular testing, as hypocalcaemia, hypokalaemia, and hypophosphataemia are commonly observed early in treatment. Liver function tests (LFTs) including ALT, AST, and total bilirubin should be monitored regularly, especially in patients with baseline hepatic impairment or HCC. Urinalysis for proteinuria is required; suspend Cabozanix for Grade 3 or above proteinuria until resolution to Grade 1 or below. Clinicians should monitor for clinical signs of haemorrhagic events (gastrointestinal bleeding, haematuria, cerebral haemorrhage), gastrointestinal perforation or fistula formation, thromboembolic events, osteonecrosis of the jaw (ONJ), and Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Thyroid function should be assessed periodically, as hypothyroidism occurs during Cabozantinib treatment.

Drug Interactions and Important Safety Information for Cabozanix (Cabozantinib)

Cabozantinib is metabolised primarily by hepatic CYP3A4 enzymes. Strong CYP3A4 inhibitors including clarithromycin, ketoconazole, itraconazole, voriconazole, and grapefruit products significantly increase Cabozantinib plasma concentrations, requiring a 20mg daily dose reduction. Strong CYP3A4 inducers including rifampin, carbamazepine, phenytoin, phenobarbital, and St. John’s Wort substantially reduce Cabozantinib exposure; where clinically necessary, increase the daily dose by 20mg up to a maximum of 80mg per day, and restore the original dose 2 to 3 days after the inducer is stopped.

Cabozantinib is a substrate and inhibitor of P-glycoprotein (P-gp), which may affect the pharmacokinetics of co-administered P-gp substrates. Concomitant anticoagulant therapy requires close monitoring for haemorrhage risk, as Cabozantinib itself increases bleeding risk. Patients should disclose all current medications, herbal supplements, and dietary habits particularly grapefruit consumption to their treating oncologist before starting Cabozanix.

Side Effects and Precautions of Cabozanix (Cabozantinib)

Who Should Use Cabozanix 20MG & 60MG (Cabozantinib)?

Cabozanix is indicated for adult oncology patients with advanced or metastatic Renal Cell Carcinoma (RCC) either as first-line combination therapy with nivolumab for intermediate or poor-risk disease, or as monotherapy following progression on prior VEGFR-targeted therapy; adult patients with Hepatocellular Carcinoma (HCC) previously treated with sorafenib; adult and paediatric patients aged 12 and above with Differentiated Thyroid Cancer (DTC) progressing on prior VEGFR-targeted therapy; and patients with Medullary Thyroid Cancer (MTC) where RET-driven signalling is central to tumorigenesis. Treatment with Cabozanix must be initiated and supervised by a qualified oncologist or specialist physician experienced in advanced cancer therapy. A pre-treatment assessment including blood pressure, electrolytes, LFTs, urinalysis, thyroid function, and evaluation for active bleeding risk or planned surgery is mandatory before starting Cabozanix. For the full range of oncology and specialty cancer medicines available through Mediaid Pharmacy, including combination partners such as nivolumab and other targeted oncology treatments, visit the oncology medicines page.

Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh and the number one oncology and specialty medicine company in the country. Beacon was the first company in Bangladesh to export cancer medicines and currently exports to markets across Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards. Cabozanix (Cabozantinib) 20mg and 60mg is one of Beacon’s flagship oncology products, offering a high-quality, bioequivalent, and affordable alternative to Cabometyx (Exelixis/Ipsen) at a fraction of the originator cost. Every batch of Cabozanix exported by Beacon meets the quality, purity, and bioequivalence requirements validated for international supply to regulated markets.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Cabozanix (Cabozantinib)

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted cancer therapy medications. Cabozanix (Cabozantinib) 20mg and 60mg is available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Europe, and beyond. Our team provides full order support including pricing, availability confirmation, export documentation, and delivery tracking for oncologists, hospitals, cancer centres, and patients requiring Cabozanix internationally. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for enquiries about pricing and delivery to your country.

Why Choose Cabozanix (Cabozantinib) from Mediaid Pharmacy?

Cabozanix represents a clinically proven advancement in the treatment of advanced kidney cancer, liver cancer, and thyroid malignancies. As the generic bioequivalent of Cabometyx (Exelixis/Ipsen), Cabozanix delivers the same active ingredient Cabozantinib with the same unique multi-kinase inhibition of VEGFR, MET, AXL, and RET, at a dramatically more affordable price. The availability of both the 20mg strength (90-tablet pot) for complete dose titration management and the 60mg strength (30-tablet pot) for standard monotherapy supply makes Cabozanix uniquely well-suited to every dosing scenario encountered in real-world advanced oncology practice. Manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy with worldwide shipping, Cabozanix is the trusted choice for oncologists and patients seeking proven, affordable multi-kinase inhibitor therapy. For a comprehensive range of oncology medicines including targeted therapies, checkpoint inhibitors, and specialty cancer treatments, visit Mediaid Pharmacy’s oncology medicines portfolio.

Frequently Asked Questions About Cabozanix 20MG & 60MG (Cabozantinib)